New Delhi, Jan 28 (NationPress) The Union Ministry of Health and Family Welfare has officially announced significant modifications to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at expediting drug development timelines and bolstering the ecosystem for clinical research and pharmaceutical innovation.

The recent amendments focus on streamlining regulatory processes, shortening approval durations, and fostering a more business-friendly environment.

These regulatory changes are set to deliver considerable advantages to stakeholders while prioritizing public health and safety. They are designed to facilitate the swift commencement of Bioavailability/Bioequivalence (BA/BE) studies, drug testing, and research evaluations, thereby minimizing delays throughout the drug development and approval processes.

According to the Ministry, “These reforms highlight the Government of India’s ongoing dedication to trust-based regulatory improvements in the pharmaceutical sector, aligned with the Jan Vishwas Siddhant and the overarching Ease of Doing Business initiative.”

The initiative is geared towards promoting R&D-led growth within the Indian pharmaceutical industry, harmonizing domestic regulations with international best practices, and reinforcing India’s stature as a preferred hub for pharmaceutical research and development.

As outlined in the amendments, the drug development lifecycle is projected to save a minimum of 90 days. For categories still requiring test licenses, the statutory processing period has been halved from 90 days to 45 days, as reported by the Ministry.

Traditionally, pharmaceutical firms have been obligated to acquire a test license from the Central Drugs Standard Control Organization (CDSCO) for the production of small drug quantities intended for examination or research. This requirement has now transitioned to a prior-intimation mechanism.

“The industry will no longer need to apply for a test license and may initiate pharmaceutical development once an online notification is submitted to the CDSCO, except for a limited set of high-risk drugs, including cytotoxic and narcotic substances,” the Ministry confirmed.

On an annual basis, the CDSCO processes roughly 30,000 to 35,000 test license applications. This new reform is expected to significantly ease regulatory burdens and benefit numerous stakeholders.

Moreover, the amendments have eliminated the need for prior authorization for specific low-risk BA/BE studies.

“Such studies may now commence with a simple online notification to the CDSCO, facilitating quicker initiation of studies, particularly beneficial for the generic pharmaceutical sector. The CDSCO typically processes about 4,000 to 4,500 BA/BE study applications each year, and the updated process is anticipated to drastically reduce procedural delays,” the Ministry stated.

Furthermore, to ensure the smooth execution of these reforms, dedicated online platforms will be accessible through the National Single Window System (NSWS) and the SUGAM portal, allowing the industry to submit notifications in a clear and efficient manner.

The reforms will also empower the CDSCO to optimize its manpower utilization, thus improving the efficiency and effectiveness of regulatory oversight.